Prediction of the differences in tumor mutation burden between primary and metastatic lesions by radiogenomics

Tumor mutational burden (TMB) is gaining attention as a biomarker for responses to immune checkpoint inhibitors in cancer patients. In this study, we evaluated the status of TMB in primary and liver metastatic lesions in patients with colorectal cancer (CRC). In addition, the status of TMB in primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoshino, Isamu, Yokota, Hajime, Iwatate, Yosuke, Mori, Yasukuni, Kuwayama, Naoki, Ishige, Fumitaka, Itami, Makiko, Uno, Takashi, Nakamura, Yuki, Tatsumi, Yasutoshi, Shimozato, Osamu, Nagase, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748253/
https://www.ncbi.nlm.nih.gov/pubmed/34689378
http://dx.doi.org/10.1111/cas.15173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748253/
https://www.ncbi.nlm.nih.gov/pubmed/34689378
http://dx.doi.org/10.1111/cas.15173

Ejemplares similares